September 2008. Volume 4. Number 3

Son necesarios más estudios para determinar el riesgo de enfermedad respiratoria aguda y exacerbación de asma tras la administración de la vacuna antigripal de virus atenuados en niños con sibilancias intermitentes

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass Ch, Glezen WP. Safety of intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008;27:444-52
Reviewers: Bernaola Aponte G1, Aparicio Sánchez JL2.
1Máster en Epidemiología Clínica. Servicio de Pediatría. Hospital Suárez Angamos. Lima. Perú.
2Servicio de Pediatría. Hospital General de Lanzarote. Gran Canaria. España.
Correspondence: Guillermo Bernaola Aponte. Email: guiber0307@hotmail.com
Reception date: 15/07/2008
Acceptance date: 07/08/2008
Publication date: 01/09/2008

Abstract

Authors’s conclusions: attenuated influenza vaccine administration in children aged 1.5-18 years with history of intermittent wheezing was not associated with increased risk for acute respiratory illnesses, nor acute asthma exacerbation.

Reviewer’s commentary: intranasal, attenuated vaccines seem to be as efficacious as inactivated influenza vaccine; however, some papers suggest an increased risk for reactive airway disease especially in children younger than 5 years. The study results showed that intranasal, attenuated vaccines were not associated with increased risk for neither acute respiratory illnesses nor asthma exacerbation in children with history of intermittent wheezing. However, higher quality studies are needed before stating recommendations for this vaccine in this group of children.

How to cite this article

Martín Muñoz P, Ruiz-Canela J. Guías de práctica clínica (I): conceptos básicos. Evid Pediatr. 2008;4:60.

AVC | Critically appraised articles

Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass Ch, Glezen WP. Safety of intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008;27:444-52
Reviewers: Bernaola Aponte G1, Aparicio Sánchez JL2.
1Máster en Epidemiología Clínica. Servicio de Pediatría. Hospital Suárez Angamos. Lima. Perú.
2Servicio de Pediatría. Hospital General de Lanzarote. Gran Canaria. España.
Correspondence: Guillermo Bernaola Aponte. Email: guiber0307@hotmail.com
Reception date: 15/07/2008
Acceptance date: 07/08/2008
Publication date: 01/09/2008

How to cite this article

Martín Muñoz P, Ruiz-Canela J. Guías de práctica clínica (I): conceptos básicos. Evid Pediatr. 2008;4:60.

References

  1. Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J. 2004;23:138-44.
  2. MedImmune Vaccines, Inc. FluMist® Influenza Virus Vaccine Live, Intranasal. Intranasal Spray 2008-2009 Formula Initial U.S. Approval: 2003 [en línea][consultado: 5-VIII-2008]. Disponible en: http://www.medimmune.com/pdf/products/flumist_pi.pdf
  3. Smith S, Demicheli V, Di Pietrantonj C, Harnden AR, Jefferson T, Matheson NJ, Rivetti A. Vacunas para la prevención de la influenza en niños sanos (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 2. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
01/09/2008

Linked Comment